drugset / Trial / NCT00419393

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

NCT00419393

Phase 3 Completed 190 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.

Timeline

Start
2007-12
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1000 mg
Subject Levetiracetam Other / unclassified 3000 mg

Indications